Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Cited by 63 Publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Adv Mater, 2018, 30(43):e1801621

PubMed: 30203567 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

J Control Release, 2019, 294:165-175

PubMed: 30557650 ( click the link to review the publication )

Redox Biol, 2019, 22:101131

PubMed: 30735911 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(12):2079-2094

PubMed: 30825187 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):64

PubMed: 31101119 ( click the link to review the publication )

Cells, 2019, 8(6)

PubMed: 31216647 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0923

PubMed: 31160383 ( click the link to review the publication )

Life Sci, 2019, 224:255-262

PubMed: 30928404 ( click the link to review the publication )

Cell Biosci, 2019, 9:20

PubMed: 30820314 ( click the link to review the publication )

Biomed Rep, 2019, 10(4):218-224

PubMed: 30972217 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1154-1159

PubMed: 31103263 ( click the link to review the publication )

Orthop Surg, 2019, 11(1):126-134

PubMed: 30592172 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3197-3203

PubMed: 29559562 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(8):e8238

PubMed: 30104419 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):743

PubMed: 29970890 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1134

PubMed: 30429459 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Biochem Pharmacol, 2018, 155:102-109

PubMed: 29953843 ( click the link to review the publication )
Front Pharmacol, 2018, 9:1116

PubMed: 30319428 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):1225

PubMed: 30526520 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Fitoterapia, 2018, 125:174-183

PubMed: 29355751 ( click the link to review the publication )

Clin Cancer Res., 2017, 23(15):4364-4375

PubMed: 28246274 ( click the link to review the publication )

Clin Chem, 2017, 63(10):1633-1641

PubMed: 28784692 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

Mol Cancer Ther, 2017, 77(22):6282-6298

PubMed: 28424227 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(7):1377-1388

PubMed: 28416606 ( click the link to review the publication )

J Cancer, 2017, 8(9):1655-1664

PubMed: 28775785 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:146

PubMed: 28491824 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Exp Ther Med, 2017, 14(5):4263-4271

PubMed: 29075340 ( click the link to review the publication )

World J Clin Oncol, 2017, 8(1):54-66

PubMed: 28246585 ( click the link to review the publication )

Oncotarget, 2017, 9(1):249-267

PubMed: 29416611 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2016, 143:463-471

PubMed: 27037784 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

Chin Med J (Engl), 2016, 129(20):2469-2475

PubMed: 27748340 ( click the link to review the publication )
ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662 ( click the link to review the publication )

Environ Sci Technol, 2015, 49(6):3575-83

PubMed: 25695909 ( click the link to review the publication )

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318 ( click the link to review the publication )

J Nanopart Res, 2014, 16:2340

PubMed: ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053 ( click the link to review the publication )

RSC Adv, 2011, 1:884-892

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMECwNlg4KM7:TR?=	MVTTRW5ITVJ?
LC-2-ad	NUL5bIRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjlPIZKSzVyPUCuNFAxOzF5IN88US=>	M13yUHNCVkeHUh?=
RL95-2	MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMECwOlY5KM7:TR?=	Ml\PV2FPT0WU
MZ1-PC	NF\MbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37Rc2lEPTB;MD6wNFA4OjlizszN	NHHze5ZUSU6JRWK=
TE-8	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjuPJNxUUN3ME2wMlAxOTF5IN88US=>	M{njbHNCVkeHUh?=
SW954	NUDGdoFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrXTWM2OD1yLkCwNVE6KM7:TR?=	M2DzcXNCVkeHUh?=
TE-11	NFjsbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4qyNmlEPTB;MD6wNFEzOyEQvF2=	NFnnUmVUSU6JRWK=
PSN1	NFXkNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoGwTWM2OD1yLkCwNVMh\|ryP	MnzUV2FPT0WU
MOLT-4	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlWyTWM2OD1yLkCwNVQ6KM7:TR?=	MX3TRW5ITVJ?
697	NWOxfmw2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVKyfmdzUUN3ME2wMlAxOTVizszN	MWTTRW5ITVJ?
ETK-1	NUfHeII3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWryXJg4UUN3ME2wMlAxOTV{IN88US=>	MoHSV2FPT0WU
TE-10	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMECxOVQh\|ryP	M3TifnNCVkeHUh?=
HUTU-80	NG\3cHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2D4RmlEPTB;MD6wNFE3QCEQvF2=	M3zBeHNCVkeHUh?=
NTERA-S-cl-D1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHn0[YNKSzVyPUCuNFAzODlizszN	MVXTRW5ITVJ?
MFH-ino	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rKWmlEPTB;MD6wNFI3QCEQvF2=	MW\TRW5ITVJ?
IA-LM	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoSyTWM2OD1yLkCwNlgh\|ryP	M{XjfXNCVkeHUh?=
MC116	NYPYUJpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnGNotWUUN3ME2wMlAxOjh7IN88US=>	NVPQSYlHW0GQR1XS
RKO	NV;YNWhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTLTWM2OD1yLkCwNlk5KM7:TR?=	MW\TRW5ITVJ?
MRK-nu-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4L1TWlEPTB;MD6wNFI6QSEQvF2=	MWLTRW5ITVJ?
VA-ES-BJ	M33BbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHqTWM2OD1yLkCwN{DPxE1?	NGLp[pFUSU6JRWK=
KALS-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMECzNFgh\|ryP	NGLHb41USU6JRWK=
BB30-HNC	NYfKSYNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGK2RmFKSzVyPUCuNFA{OTRizszN	MnniV2FPT0WU
ACN	M3zaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLDNWFKSzVyPUCuNFA{OTZizszN	MX\TRW5ITVJ?
TE-9	MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHmZY5KSzVyPUCuNFA{OjZizszN	MYLTRW5ITVJ?
SIG-M5	M2DMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLPTXp2UUN3ME2wMlAxOzJ5IN88US=>	MnrEV2FPT0WU
no-10	NFHqe\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLpWWZSUUN3ME2wMlAxOzZ{IN88US=>	MVLTRW5ITVJ?
EW-1	M{XrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn4SXFKSzVyPUCuNFA{PzFizszN	MlLyV2FPT0WU
SK-LMS-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMEC0NFEh\|ryP	NX7BPGQ5W0GQR1XS
GT3TKB	M3HGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMEC0N\|Qh\|ryP	MULTRW5ITVJ?
ES4	NGTqfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4WzdWlEPTB;MD6wNFQ1QSEQvF2=	MUDTRW5ITVJ?
IMR-5	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\2TWM2OD1yLkCwOFUh\|ryP	NF7YSYhUSU6JRWK=
NCI-H1648	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XUOmlEPTB;MD6wNFQ3QSEQvF2=	Mm\BV2FPT0WU
MV-4-11	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL1TmtKSzVyPUCuNFA1PzVizszN	MlT2V2FPT0WU
SK-UT-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLxe49KSzVyPUCuNFA1QCEQvF2=	NVnNOnJCW0GQR1XS
NB13	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMEC0PVEh\|ryP	NVv6SHhlW0GQR1XS
DJM-1	MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfjfWdkUUN3ME2wMlAxPTNizszN	NXiwUGNOW0GQR1XS
ES8	NX72UXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfpO2pvUUN3ME2wMlAxPTN6IN88US=>	NFKx[5hUSU6JRWK=
TE-6	NWSzOI86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnoTWM2OD1yLkCwOVch\|ryP	NXX5e2o4W0GQR1XS
KS-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrnfZlKSzVyPUCuNFA2QDJizszN	NYrGPXFbW0GQR1XS
TE-1	MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMEC2NFYh\|ryP	M3TqS3NCVkeHUh?=
ATN-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTGdZE2UUN3ME2wMlAxPjB7IN88US=>	M1nx[3NCVkeHUh?=
A4-Fuk	M1;VO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPZTWM2OD1yLkCwOlEyKM7:TR?=	MVzTRW5ITVJ?
ALL-PO	NYfJVHh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLWTWM2OD1yLkCwOlMh\|ryP	NIewUVFUSU6JRWK=
BE-13	MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\WVWdKSzVyPUCuNFA3OzZizszN	MWXTRW5ITVJ?
KM12	NFPiPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMEC2N\|ch\|ryP	NVrscmZnW0GQR1XS
NOS-1	M4jBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPKTWM2OD1yLkCwOlUh\|ryP	M4nE[3NCVkeHUh?=
SW962	NH3KdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH2xWmFKSzVyPUCuNFA3PjJizszN	M{fabXNCVkeHUh?=
OCUB-M	M2rISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMEC2OlIh\|ryP	MmfkV2FPT0WU
NCI-H510A	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnFb5cyUUN3ME2wMlAxPjZ3IN88US=>	NXe1UWpuW0GQR1XS
EW-16	NVTnSYxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TZcGlEPTB;MD6wNFY6PCEQvF2=	M4WxfHNCVkeHUh?=
KGN	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEC3NVIh\|ryP	NWfJPXBvW0GQR1XS
LS-411N	NVLLdplNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\uRVZtUUN3ME2wMlAxPzF5IN88US=>	NEnabXVUSU6JRWK=
Becker	NEewN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPRenl5UUN3ME2wMlAxPzJizszN	MmHwV2FPT0WU
HC-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXsd\|lyUUN3ME2wMlAxPzJzIN88US=>	MkLGV2FPT0WU
CESS	M2XUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTkUFlHUUN3ME2wMlAxPzN5IN88US=>	M2H4eXNCVkeHUh?=
KURAMOCHI	NHr4VYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrITWM2OD1yLkCwO\|Q5KM7:TR?=	NWXxU\|M4W0GQR1XS
TGBC24TKB	NFi2NoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHvfplKSzVyPUCuNFA4PTJizszN	NUnCfGdSW0GQR1XS
SW982	MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XMbGlEPTB;MD6wNFc3PiEQvF2=	MWjTRW5ITVJ?
HCE-4	NWm4RYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMEC3Olch\|ryP	MVHTRW5ITVJ?
LOUCY	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEC3O\|Uh\|ryP	M4f2XXNCVkeHUh?=
8-MG-BA	NYfJcYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;MTWM2OD1yLkCwO\|k3KM7:TR?=	MWnTRW5ITVJ?
HT-144	NEfzSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrVXHkyUUN3ME2wMlAxQCEQvF2=	M3zqenNCVkeHUh?=
LXF-289	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMEC4NVgh\|ryP	NWj1TZEyW0GQR1XS
RS4-11	NFjjT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NID4XGRKSzVyPUCuNFA5OzZizszN	M4TjV3NCVkeHUh?=
DEL	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfVOIZsUUN3ME2wMlAxQDR3IN88US=>	MXXTRW5ITVJ?
OCI-AML2	M{nDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlmzTWM2OD1yLkCwPFUzKM7:TR?=	M4TQ[3NCVkeHUh?=
CCRF-CEM	M4ftNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMEC4O\|Eh\|ryP	M3TEdnNCVkeHUh?=
A388	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMEC4O\|Qh\|ryP	NGi1U45USU6JRWK=
KNS-42	MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\JWmlEPTB;MD6wNFg6OSEQvF2=	NUP3PWhjW0GQR1XS
OVCAR-4	NWjnSYdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTBwMEC5NFQh\|ryP	MX;TRW5ITVJ?
NCI-H1355	NHj4cZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\0TWM2OD1yLkCwPVE1KM7:TR?=	M4\1bXNCVkeHUh?=
BL-70	MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULuWVhQUUN3ME2wMlAxQTNizszN	M3zYdnNCVkeHUh?=
BL-41	NHTSSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTVO5V[UUN3ME2wMlAxQTN2IN88US=>	NIjUTGpUSU6JRWK=
A101D	NYjJNVFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVz5fGNmUUN3ME2wMlAxQTZizszN	MoHnV2FPT0WU
HL-60	M2\1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTxTWM2OD1yLkCwPVY3KM7:TR?=	NWqwb4pMW0GQR1XS
COR-L279	NF\rV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEC5PVkh\|ryP	NFG4SXZUSU6JRWK=
NCI-SNU-16	NYLJS5c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7iT4RlUUN3ME2wMlAyODB6IN88US=>	MlfRV2FPT0WU
Calu-6	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[4NoJKSzVyPUCuNFExOTJizszN	NH\icVdUSU6JRWK=
SR	NVTxd45OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfDPWkyUUN3ME2wMlAyODJ4IN88US=>	MXHTRW5ITVJ?
QIMR-WIL	NEm3UWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnW4TWM2OD1yLkCxNFM{KM7:TR?=	M2fIeXNCVkeHUh?=
LB647-SCLC	M1jaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFG5[oFKSzVyPUCuNFExPTFizszN	NID1WnZUSU6JRWK=
RPMI-8226	NU\zcWxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnwTWM2OD1yLkCxNVAzKM7:TR?=	MX7TRW5ITVJ?
SK-PN-DW	M33JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVG4d\|VqUUN3ME2wMlAyOTF{IN88US=>	NIrVTIhUSU6JRWK=
SF268	M1XpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMEGxOVEh\|ryP	MoDEV2FPT0WU
HD-MY-Z	NYXYN4xiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rtfWlEPTB;MD6wNVE3OyEQvF2=	Mn3CV2FPT0WU
DOHH-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMEGyNFMh\|ryP	M2XnWHNCVkeHUh?=
SCC-3	M3X0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMEGyNFQh\|ryP	NX\vVJZDW0GQR1XS
ST486	M{n0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXLRm9KSzVyPUCuNFEzODRizszN	M2H6c3NCVkeHUh?=
NALM-6	NF\oUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjvTWM2OD1yLkCxNlE1KM7:TR?=	M2j1[XNCVkeHUh?=
NCI-H1436	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPvSHRKSzVyPUCuNFEzOzFizszN	MX7TRW5ITVJ?
KE-37	M4\uTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMEGyN\|Qh\|ryP	NEDwXYpUSU6JRWK=
RPMI-8402	NIK1XlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMEGyOVYh\|ryP	NIfYbYZUSU6JRWK=
RXF393	M3vqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjzTYNKSzVyPUCuNFEzPTdizszN	MkHkV2FPT0WU
KARPAS-45	NXLwVWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonaTWM2OD1yLkCxNlch\|ryP	M1;rPHNCVkeHUh?=
HOP-62	NFjiU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zWRmlEPTB;MD6wNVI4PiEQvF2=	MXXTRW5ITVJ?
ES1	NGq2UYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nERWlEPTB;MD6wNVI5QCEQvF2=	MoPRV2FPT0WU
L-363	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPCTWM2OD1yLkCxN\|UyKM7:TR?=	NYK2Zlk5W0GQR1XS
GI-1	MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMEGzO\|Mh\|ryP	NE\ocZZUSU6JRWK=
CTV-1	NHPUXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;lZ5k2UUN3ME2wMlAyPDd6IN88US=>	MnGwV2FPT0WU
TE-5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\XdVFNUUN3ME2wMlAyPDl4IN88US=>	NUHje2FmW0GQR1XS
SNU-C2B	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHT5[21KSzVyPUCuNFE1QTZizszN	M3z4VnNCVkeHUh?=
K-562	MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLJTWM2OD1yLkCxOVE3KM7:TR?=	MX3TRW5ITVJ?
SNB75	MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nDdGlEPTB;MD6wNVU1KM7:TR?=	NHH5XHZUSU6JRWK=
MOLT-13	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PBVmlEPTB;MD6wNVY{PyEQvF2=	M{S2d3NCVkeHUh?=
LS-123	NVPwW5I5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;iXm5OUUN3ME2wMlAyPjZ2IN88US=>	MoPHV2FPT0WU
NCI-SNU-5	M{K1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIKwfYRKSzVyPUCuNFE4ODFizszN	NVvueJhUW0GQR1XS
Daudi	NGfoPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPRUlhFUUN3ME2wMlAyPzB6IN88US=>	NIixNmRUSU6JRWK=
A253	NEHBWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TPSGlEPTB;MD6wNVc{QCEQvF2=	Mlm5V2FPT0WU
TGBC1TKB	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13tW2lEPTB;MD6wNVc2OiEQvF2=	Mlm3V2FPT0WU
SJSA-1	NGT5T\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI[zSWhKSzVyPUCuNFE4PjdizszN	NYXyUJBwW0GQR1XS
NCCIT	M{G1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULJV3d4UUN3ME2wMlAyPzZ7IN88US=>	MnHhV2FPT0WU
NCI-H69	NGThZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGT2XoZKSzVyPUCuNFE4PzhizszN	MYXTRW5ITVJ?
SH-4	NFPUZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vpTmlEPTB;MD6wNVg6PSEQvF2=	MlPCV2FPT0WU
HCC1187	M{PCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jRN2lEPTB;MD6wNVkzPCEQvF2=	MUPTRW5ITVJ?
HCC1599	NVfWWJBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1v0TGlEPTB;MD6wNlAzKM7:TR?=	MlfoV2FPT0WU
ONS-76	M2\TXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3niTmlEPTB;MD6wNlA{PiEQvF2=	NW\2dZo4W0GQR1XS
KU812	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFexe5NKSzVyPUCuNFIxOzlizszN	MX\TRW5ITVJ?
ML-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zqTWlEPTB;MD6wNlA1PyEQvF2=	M3rIeHNCVkeHUh?=
HCE-T	NVn3S3JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPXUJJKSzVyPUCuNFIxQTJizszN	Mk\vV2FPT0WU
NCI-H446	NG\WeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjPTWM2OD1yLkCyNVEzKM7:TR?=	MoXIV2FPT0WU
RPMI-6666	NG\JZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUmxW2hyUUN3ME2wMlAzOTR7IN88US=>	M1:3PXNCVkeHUh?=
MOLT-16	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfxO\|ZnUUN3ME2wMlAzOTV\|IN88US=>	NWmxU\|JoW0GQR1XS
JiyoyeP-2003	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofYTWM2OD1yLkCyNVc3KM7:TR?=	M{fNS3NCVkeHUh?=
MHH-PREB-1	M1;FUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjlV5ZRUUN3ME2wMlAzOTlzIN88US=>	MYjTRW5ITVJ?
MC-CAR	NEXGN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LhTGlEPTB;MD6wNlMzPiEQvF2=	MmPsV2FPT0WU
BC-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfLTWM2OD1yLkCyN\|Q1KM7:TR?=	MnzuV2FPT0WU
KINGS-1	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXR[5hKSzVyPUCuNFI{PTVizszN	Mn;jV2FPT0WU
PF-382	NI[xXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml73TWM2OD1yLkCyN\|c5KM7:TR?=	MYLTRW5ITVJ?
J-RT3-T3-5	NIfTSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2i4d2lEPTB;MD6wNlM5OyEQvF2=	MVTTRW5ITVJ?
SF539	NWHJbmtoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPDTm1mUUN3ME2wMlAzPDBzIN88US=>	MlvLV2FPT0WU
LB831-BLC	NGXTWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDmWJc{UUN3ME2wMlAzPDh3IN88US=>	NVPOWVJwW0GQR1XS
DMS-114	MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLQeWNRUUN3ME2wMlAzPTB{IN88US=>	M4nUeHNCVkeHUh?=
LB1047-RCC	NX;xfY55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHmZ5NKSzVyPUCuNFI2OSEQvF2=	NF7sNFRUSU6JRWK=
LB771-HNC	MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnQToRKSzVyPUCuNFI2OzRizszN	NX[0WHA2W0GQR1XS
BB65-RCC	NULsTlV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;i[GlEPTB;MD6wNlU{PCEQvF2=	NY\DW2M1W0GQR1XS
BV-173	MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DJNGlEPTB;MD6wNlU2PCEQvF2=	M1XGbXNCVkeHUh?=
ARH-77	M1H3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPqXpVOUUN3ME2wMlAzPjBzIN88US=>	NEDzbVlUSU6JRWK=
IST-MEL1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMEK2NlMh\|ryP	M{TaU3NCVkeHUh?=
NB1	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfXNnhlUUN3ME2wMlAzPjh5IN88US=>	MUDTRW5ITVJ?
EoL-1-cell	NFHxcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2O0TGlEPTB;MD6wNlY5QCEQvF2=	MXHTRW5ITVJ?
KY821	M{fCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HFSGlEPTB;MD6wNlY6PyEQvF2=	MmXyV2FPT0WU
CMK	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHyweFZKSzVyPUCuNFI4OzRizszN	MVTTRW5ITVJ?
NCI-H2126	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zEd2lEPTB;MD6wNlc3QCEQvF2=	M3TOfnNCVkeHUh?=
NCI-H526	M1LQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfmTWM2OD1yLkCyPFkyKM7:TR?=	MXXTRW5ITVJ?
COLO-684	MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMEK5NFgh\|ryP	MVXTRW5ITVJ?
NCI-H747	NWjHcHFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXETWM2OD1yLkCyPVM{KM7:TR?=	M1W5bnNCVkeHUh?=
JAR	MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwMEK5OFYh\|ryP	M1nRR3NCVkeHUh?=
MEG-01	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITIbpBKSzVyPUCuNFI6PzhizszN	MYHTRW5ITVJ?
MONO-MAC-6	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rqXmlEPTB;MD6wN\|AzOyEQvF2=	MkC2V2FPT0WU
IST-SL1	NFnnWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2WzbGlEPTB;MD6wN\|A1OiEQvF2=	NXnuV4RmW0GQR1XS
CPC-N	M4HZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEThOmhKSzVyPUCuNFMxPzlizszN	NFvYVGdUSU6JRWK=
NCI-H1963	M4POW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fqXmlEPTB;MD6wN\|E{OSEQvF2=	M1rTfnNCVkeHUh?=
K052	NUna[oxwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPzWY06UUN3ME2wMlA{OjR5IN88US=>	MlP6V2FPT0WU
KM-H2	NXqwfW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnL4TWM2OD1yLkCzN\|A4KM7:TR?=	M3LLWnNCVkeHUh?=
TE-12	NXjLVYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLsTWM2OD1yLkCzN\|A6KM7:TR?=	M1LoXXNCVkeHUh?=
TK10	NWrzdXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f0cWlEPTB;MD6wN\|M2PiEQvF2=	NFy5PXhUSU6JRWK=
NMC-G1	NEPTV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LHOWlEPTB;MD6wN\|Q2OiEQvF2=	NVT4SlR{W0GQR1XS
no-11	NGLNc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;5e\|ROUUN3ME2wMlA{PDd6IN88US=>	M{C5OnNCVkeHUh?=
NCI-H524	NWrSOWdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrD[ZRKSzVyPUCuNFM2OjlizszN	MWjTRW5ITVJ?
MHH-CALL-2	MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzreVhKSzVyPUCuNFM2PjJizszN	NYXqSXBbW0GQR1XS
GB-1	M174cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\MTWM2OD1yLkCzOkDPxE1?	MlPWV2FPT0WU
OPM-2	NFL1cpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13Vb2lEPTB;MD6wN\|Y4OyEQvF2=	MlvZV2FPT0WU
RH-1	M4K2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PFcWlEPTB;MD6wN\|gyQSEQvF2=	NEfkWGhUSU6JRWK=
NCI-H64	M2\SU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\zOWlEPTB;MD6wN\|g2PyEQvF2=	NHizVlVUSU6JRWK=
EVSA-T	NXPjcllET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMEO5NlMh\|ryP	MYDTRW5ITVJ?
KARPAS-299	NF\wfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmKxTWM2OD1yLkCzPVgh\|ryP	MmjPV2FPT0WU
MZ7-mel	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzqXmV6UUN3ME2wMlA1ODRizszN	NVTFcINHW0GQR1XS
LB373-MEL-D	NETuWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTOTWM2OD1yLkC0NVA2KM7:TR?=	M3;YZnNCVkeHUh?=
HEL	M{G5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[5fmdKSzVyPUCuNFQyPCEQvF2=	NFjpZodUSU6JRWK=
SW872	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1L0b2lEPTB;MD6wOFIyKM7:TR?=	M3PYe3NCVkeHUh?=
DU-4475	NFPKbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPZc4VKSzVyPUCuNFQzPDRizszN	NXvzWFVwW0GQR1XS
IST-SL2	MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGO2NZBKSzVyPUCuNFQzPzVizszN	NI\0OYRUSU6JRWK=
NCI-H82	NIfKRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoT0TWM2OD1yLkC0N\|A4KM7:TR?=	NVnKc4p3W0GQR1XS
LC4-1	M3zBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHmTWM2OD1yLkC0N\|UyKM7:TR?=	M2rtW3NCVkeHUh?=
HDLM-2	MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1W5OWlEPTB;MD6wOFM6OiEQvF2=	NV3ETY9SW0GQR1XS
MMAC-SF	M{nWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPQTos2UUN3ME2wMlA1PTN2IN88US=>	M2DFXXNCVkeHUh?=
L-540	NITxToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\CcFA5UUN3ME2wMlA1PjN7IN88US=>	M4nXcnNCVkeHUh?=
MZ2-MEL	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFT5fZJKSzVyPUCuNFQ4PDJizszN	NGnoWWtUSU6JRWK=
LU-134-A	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFW0Z41KSzVyPUCuNFQ4PzNizszN	NWrvSoJFW0GQR1XS
UACC-257	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1K3VGlEPTB;MD6wOFg1QSEQvF2=	MoDuV2FPT0WU
NCI-H1581	MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PvSmlEPTB;MD6wOFk2OyEQvF2=	NHnuXJpUSU6JRWK=
NB17	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUW1cGN1UUN3ME2wMlA1QTd7IN88US=>	MUXTRW5ITVJ?
SBC-1	NWLSdnZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLT[XFKSzVyPUCuNFUxPDJizszN	MVzTRW5ITVJ?
TALL-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmH2TWM2OD1yLkC1NFQ2KM7:TR?=	MnXuV2FPT0WU
NCI-H1304	NH\hXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\QTWM2OD1yLkC1NlA5KM7:TR?=	NYHB[mlSW0GQR1XS
NEC8	M33vXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDSSpNKSzVyPUCuNFUzQDZizszN	M1ewdXNCVkeHUh?=
CAL-148	NYDw[VlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rsWWlEPTB;MD6wOVQ{QSEQvF2=	MUnTRW5ITVJ?
CGTH-W-1	NVfNclhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMEW0OFkh\|ryP	NWCyVodLW0GQR1XS
NCI-H889	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\iTWM2OD1yLkC1OVkzKM7:TR?=	NFr6Z2xUSU6JRWK=
GR-ST	NHLpfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4r2NGlEPTB;MD6wOVYzOSEQvF2=	M4O4OXNCVkeHUh?=
KARPAS-422	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorPTWM2OD1yLkC1OlUh\|ryP	M1;KRXNCVkeHUh?=
RPMI-8866	NYjybFVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMEW3NVIh\|ryP	M4rPUHNCVkeHUh?=
SCLC-21H	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfCcm1nUUN3ME2wMlA2QDh2IN88US=>	M2rDUHNCVkeHUh?=
COR-L88	NHrMb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDsdoNnUUN3ME2wMlA2QTJ5IN88US=>	NWTXco93W0GQR1XS
LU-139	M3;pZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\TVmlEPTB;MD6wOVk5PiEQvF2=	MYHTRW5ITVJ?
SF126	NWXoeldzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rmd2lEPTB;MD6wOlE{OyEQvF2=	MnWxV2FPT0WU
NCI-H1882	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fkNGlEPTB;MD6wOlQzPCEQvF2=	MlyxV2FPT0WU
EW-24	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7nTWM2OD1yLkC2OFg{KM7:TR?=	Mk[0V2FPT0WU
CP67-MEL	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUeyd2ZXUUN3ME2wMlA3QDFizszN	M4qyfnNCVkeHUh?=
DG-75	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLFTWM2OD1yLkC2PFk6KM7:TR?=	Ml[zV2FPT0WU
LOXIMVI	NGTUS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYq2bmVwUUN3ME2wMlA4ODJ6IN88US=>	MmSxV2FPT0WU
HH	NXXNZ2J1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXjTWM2OD1yLkC3NVU4KM7:TR?=	MlHzV2FPT0WU
K5	M17CXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HZTWlEPTB;MD6wO\|IzPiEQvF2=	NETn[GtUSU6JRWK=
EC-GI-10	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnvfVlKSzVyPUCuNFczPTdizszN	NVHKXmp4W0GQR1XS
SK-N-DZ	M3:2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMEezNFch\|ryP	NYrSZZNWW0GQR1XS
A3-KAW	NYXHWVJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUK1VYlHUUN3ME2wMlA4OzVzIN88US=>	NEj0UnpUSU6JRWK=
MLMA	M2fTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXl[mpKSzVyPUCuNFc1PjVizszN	NVz2UWtQW0GQR1XS
LB996-RCC	Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\wc3NKSzVyPUCuNFc4ODdizszN	NFPGVGRUSU6JRWK=
OS-RC-2	NFzi[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETuN3hKSzVyPUCuNFc4PDhizszN	M3PuNHNCVkeHUh?=
CTB-1	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMEe4NUDPxE1?	Mkn6V2FPT0WU
IST-MES1	NXTHUJlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHL6fXZKSzVyPUCuNFc6OTJizszN	MYrTRW5ITVJ?
LS-1034	NXfEOIFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjsS3ZKSzVyPUCuNFgxOzVizszN	MWXTRW5ITVJ?
HT	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMEiwPFYh\|ryP	NV3zdJY3W0GQR1XS
NCI-H2141	NEPaUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfv[m9KSzVyPUCuNFgyKM7:TR?=	MnryV2FPT0WU
LB2518-MEL	NWL0[G1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;5Vow4UUN3ME2wMlA5OTRzIN88US=>	NWPUOJNTW0GQR1XS
GI-ME-N	NE\hUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzQOIZKSzVyPUCuNFg1PTJizszN	MV7TRW5ITVJ?
TGW	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\0TWM2OD1yLkC4OlA4KM7:TR?=	NIHqdIVUSU6JRWK=
SK-NEP-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnu2TWM2OD1yLkC4OlQyKM7:TR?=	M{Wyd3NCVkeHUh?=
NOMO-1	Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXMNpFKSzVyPUCuNFkzPzVizszN	M{fpb3NCVkeHUh?=
ES6	M4nkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjYdZR1UUN3ME2wMlA6PTh7IN88US=>	MnW4V2FPT0WU
NCI-H209	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXmdHFKSzVyPUCuNFk4QDZizszN	MV\TRW5ITVJ?
GAK	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrSTWM2OD1yLkGwNVYh\|ryP	MVvTRW5ITVJ?
BC-1	MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{C5fmlEPTB;MD6xNFM3OSEQvF2=	MYLTRW5ITVJ?
KLE	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvCTWM2OD1yLkGwOFQ{KM7:TR?=	NVX0cJR{W0GQR1XS
EW-3	M2jGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;Gc5pKSzVyPUCuNVA6QCEQvF2=	M{O3O3NCVkeHUh?=
NKM-1	MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP5WHVKSzVyPUCuNVEyKM7:TR?=	MnvRV2FPT0WU
D-336MG	M1;WVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2T1OWlEPTB;MD6xNVI1PCEQvF2=	MmC3V2FPT0WU
NB69	Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\SN5hKSzVyPUCuNVE{ODFizszN	MkO3V2FPT0WU
D-263MG	M3\nUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorsTWM2OD1yLkGxO\|EzKM7:TR?=	NV7yPY1YW0GQR1XS
KP-N-YS	NX;uZWJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmOyTWM2OD1yLkGyNlkyKM7:TR?=	NFWxUXRUSU6JRWK=
NCI-H1155	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHUTWM2OD1yLkGyOVU5KM7:TR?=	NV;YbopnW0GQR1XS
BOKU	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;6TWM2OD1yLkGyOVc6KM7:TR?=	NEj3cpBUSU6JRWK=
LAMA-84	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3KWZoxUUN3ME2wMlEzQTlizszN	Ml\tV2FPT0WU
Raji	MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTOTWM2OD1yLkGzNVE4KM7:TR?=	M1TEOHNCVkeHUh?=
LU-65	Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMUOzNFch\|ryP	M33h[HNCVkeHUh?=
NCI-H187	NILTZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[yTmJKSzVyPUCuNVM6OjRizszN	M2[0PXNCVkeHUh?=
GCIY	M{iyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlH1TWM2OD1yLkG0PVAyKM7:TR?=	MYTTRW5ITVJ?
NCI-H2107	NE\pdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTOWo1EUUN3ME2wMlE2ODhizszN	NEPXUGxUSU6JRWK=
NCI-H1522	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPTTWM2OD1yLkG1NlY3KM7:TR?=	NXXTboxwW0GQR1XS
NB6	NYXVd4NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwMUW2NlMh\|ryP	MX3TRW5ITVJ?
EM-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnDTWM2OD1yLkG1O\|A3KM7:TR?=	MWXTRW5ITVJ?
HCC2218	NWDqSYtGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDiTWM2OD1yLkG1PVgh\|ryP	NUnZVJN[W0GQR1XS
NCI-H748	NELjRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;LTWM2OD1yLkG2N\|c3KM7:TR?=	NXrIXIxtW0GQR1XS
MS-1	MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjGeFRKSzVyPUCuNVY2OzdizszN	MnnYV2FPT0WU
NB5	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzz[nlKSzVyPUCuNVY2QTdizszN	NV\6RoZrW0GQR1XS
OMC-1	M322[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELoNVBKSzVyPUCuNVY3QDhizszN	NVzSbYUxW0GQR1XS
NCI-H345	NYPH[ZZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\kVWlEPTB;MD6xOlkzQCEQvF2=	MUjTRW5ITVJ?
L-428	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7adpRKSzVyPUCuNVY6PDVizszN	MX3TRW5ITVJ?
SCH	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMUi2PFUh\|ryP	NGHIdndUSU6JRWK=
NCI-H1417	NET2T\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vjNmlEPTB;MD6xPVIzPyEQvF2=	M{jtN3NCVkeHUh?=
COLO-320-HSR	NHOzN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMUm1N\|Ih\|ryP	NFP4NohUSU6JRWK=
BT-474	NYL6OY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwMkC4PVIh\|ryP	NV\xcFM5W0GQR1XS
GDM-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmm3TWM2OD1yLkKxPVcyKM7:TR?=	MYPTRW5ITVJ?
NCI-H2196	NHvpcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHFOI1KSzVyPUCuNlIzOzVizszN	MmHWV2FPT0WU
KP-N-RT-BM-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofwTWM2OD1yLkKyN\|Q6KM7:TR?=	Mn;SV2FPT0WU
KNS-81-FD	NGntZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTqZpdUUUN3ME2wMlIzQTV6IN88US=>	NInldItUSU6JRWK=
COLO-668	NHrV[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7vfotKSzVyPUCuNlM3PzVizszN	NFq2bZdUSU6JRWK=
C2BBe1	NF\wVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFO0RmdKSzVyPUCuNlY4PDdizszN	M1T0XHNCVkeHUh?=
Ramos-2G6-4C10	NUHoe5dsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLQboluUUN3ME2wMlI3QTV2IN88US=>	MkXUV2FPT0WU
CAS-1	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4njTGlEPTB;MD6yO\|A6PiEQvF2=	M3;2OnNCVkeHUh?=
GOTO	NY[wW41FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moe1TWM2OD1yLkK3PFk1KM7:TR?=	NHHtcJRUSU6JRWK=
LP-1	NXjEZZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\aZ2lEPTB;MD6yPFA2PyEQvF2=	MlXtV2FPT0WU
NCI-SNU-1	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVn5R\|Z2UUN3ME2wMlI6PDJ{IN88US=>	M2HmdnNCVkeHUh?=
EB-3	MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PjVmlEPTB;MD6yPVk4QSEQvF2=	Mmr4V2FPT0WU
MHH-NB-11	NFTNOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwM{C0NFIh\|ryP	MYLTRW5ITVJ?
SK-N-FI	M33kR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwM{G2PVIh\|ryP	MoL6V2FPT0WU
HCC2157	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2n3eWlEPTB;MD6zN\|kyOyEQvF2=	NXG0c2k4W0GQR1XS
SIMA	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\TRnlUUUN3ME2wMlM1PThzIN88US=>	NVz6OnhSW0GQR1XS
MDA-MB-134-VI	NYrDTlk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFf0S3lKSzVyPUCuN\|Y6OjhizszN	M{jyT3NCVkeHUh?=
NCI-H1694	MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLVZpRNUUN3ME2wMlM4KM7:TR?=	NV2wd2h7W0GQR1XS
EHEB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwM{mwPFUh\|ryP	M{nMVnNCVkeHUh?=
U-266	NIrXRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;DTWlEPTB;MD6zPVg1PiEQvF2=	MkXOV2FPT0WU
LC-1F	NEO1bFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LxTWlEPTB;MD60N\|c3PSEQvF2=	M1PNZnNCVkeHUh?=
SHP-77	NFroUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;lTWM2OD1yLkS3PFU2KM7:TR?=	NF;SPGRUSU6JRWK=
LS-513	MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHHbGFKSzVyPUCuOFk{ODdizszN	M{fVPHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK; PubMed: 20068074 Clin Cancer Res Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells. MARCKS (pSer159/163); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. Src (pTyr416); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; PubMed: 29849942 Oncotarget OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot. Id1; PubMed: 25344919 Oncotarget (A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner. MARCKS; PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.	20068074 26015406 29849942 25344919
Growth inhibition assay	Cell viability; PubMed: 28823711 Biol Psychiatry Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.	28823711
Immunofluorescence	α-tubulin; PubMed: 22904633 Int J Nanomedicine Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel. Rab11a/BV9; PubMed: 29290815 Theranostics Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).	22904633 29290815

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research: ^[1]	+ Expand Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs Concentrations: 0.1-100 pM Incubation Time: 72 hours Method: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well. (Only for Reference)
Animal Research: ^[4]	+ Expand Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use. Dosages: 20 mg/kg Administration: Administered via i.v. (Only for Reference)

Cell Research:

^[1]

+ Expand

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[4]

+ Expand

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

+ Expand

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Ethanol	18 mg/mL (21.07 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 125973

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04000906	Not yet recruiting	Drug: NAB paclitaxel\|Drug: Cisplatin	Peritoneal Carcinomatosis	University Hospital Geneva	September 2019	Phase 1
NCT04046887	Not yet recruiting	Drug: Lonsurf\|Drug: Gemcitabine\|Drug: Nab-Paclitaxel	Pancreatic Cancer\|Pancreatic Ductal Adenocarcinoma	Patrick Joseph Loehrer Sr.\|Indiana University\|Taiho Oncology Inc.	August 2019	Phase 1
NCT03779464	Recruiting	Drug: S1 or Gemcitabine	Pancreatic Cancer\|Nab-paclitaxel\|Gemcitabine\|S1	Wuhan Union Hospital China	August 1 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (EPO906, Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 63 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 63 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)